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The introduction of highly active antiretroviral therapy during the 1990s was crucial to the
decline in the rates of morbidity and death related to the acquired immunodeﬁciency syn-
drome (AIDS) and turned human immunodeﬁciency virus (HIV) infection into a chronic
condition. Consequently, the HIV/AIDS population is becoming older. The aim of this study
was to describe the immunological, clinical and comorbidity proﬁle of an urban cohort
of patients with HIV/AIDS followed up at Instituto de Pesquisa Clinica Evandro Chagas,
Oswaldo Cruz Foundation in Rio de Janeiro, Brazil. Retrospective data from 2307 patients
during January 1st, 2008 and December 31st, 2008 were collected. For continuous variables,
Cuzick’s non-parametric test was used. For categorical variables, the Cochran–Armitage
non-parametric test for tendency was used. For all tests, the threshold for statistical signif-
icance was set at 5%. In 2008, 1023 (44.3%), 823 (35.7%), 352 (15.3%) and 109 (4.7%) were aged
18–39, 40–49, 50–59 and ≥60 years-old, respectively. Older and elderly patients (≥40 years)
were more likely to have viral suppression than younger patients (18–39 years) (p<0.001). No
signiﬁcant difference in the latest CD4+ T lymphocyte count in the different age strata was
observed, although elderly patients (≥ 50 years) had lowerCD4+ T lymphocyte nadir (p<0.02).
The number of comorbidities increased with age and the same pattern was observed for
the majority of the comorbidities, including diabetes mellitus, dyslipidemia, hypertension,
cardiovascular diseases, erectile dysfunction, HCV, renal dysfunction and also for non-AIDS-
related cancers (p<0.001). With the survival increase associated to successful antiretroviral
therapy and with the increasing new infections among elderly group, the burden associ-ated to the diagnosis and treatment of the non-AIDS related HIV comorbidities will grow.
Longitudinal studies on the impact of aging on the HIV/AIDS population are still necessary,
especially in resource-limited countries.
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND∗ Corresponding author at: Av. Brasil, 4365 Manguinhos, Rio de Janeiro,
E-mail address: gbeatriz@ipec.ﬁocruz.br (B. Grinsztejn).
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Statistical comparison of quantitative variables across decade
of life was accessed by the Cuzick’s non-parametric test forbraz j infect d i s .
ntroduction
orldwide, life expectancy has been increasing over the last
everal decades, even in developing countries, leading to a
reater number of individuals≥60 years. Therewill be approx-
mately 2 billion people ≥60 years in the world by 2025, the
ajority of whom (80%) will reside in developing countries.1
ccording to the Brazilian Institute of Geography and Statis-
ics (IBGE), 97% of the Brazilian population at the beginning
f the 20th century was younger than 59 years; currently, 15.8
illion Brazilians are at least 60 years old, and this number is
stimated to increase to more than 40 million by 2030. Overall,
ife expectancyof theBrazilianpopulationby 2030 is estimated
o be 78.3 years, 81.9 years for women.2
The introduction of highly active antiretroviral therapy
HAART) during the 1990s was crucial to reduce HIV-related
orbidity and mortality rates turning HIV infection into a
hronic condition. Antiretroviral therapy (ART) global coverage
as signiﬁcantly grown in the latest years, with 11.7 million
ife-years added to the world between 1996 and 2008.3 Con-
equently, the HIV/AIDS population is becoming older. The
orld HealthOrganization (WHO) and themajority of geriatri-
ians deﬁne “elderly” as a person aged≥60 years. However, the
merican Centers for Disease Control and Prevention (CDC)
onsiders a patient with HIV/AIDS at the age of 50 years to be
lderly due to the impact of HIV and ART on aging.4 Accord-
ng to the Brazilian Ministry of Health, among the 608,230
ases of HIV/AIDS notiﬁed up to June 2011; 64,560 (10.6%) were
n the elderly group (≥50 years).5Chronic conditions asso-
iated with aging such as non-AIDS-deﬁning malignancies,
ardiovascular diseases and other end-organ diseases and
eaths attributable to these conditions have also increased in
IV/AIDS cohorts.6–9
The aim of this study was to describe the immunologi-
al, clinical and comorbidity proﬁle across age of an urban
ohort of patients with HIV/AIDS followed up at a referral
enter for HIV care and research in Rio de Janeiro, Brazil, in
008.
ethods
escription of the clinical cohort and study population
his study was conducted at Instituto de Pesquisa Clinica
vandro Chagas, Oswaldo Cruz Foundation (IPEC/FIOCRUZ),
here care has been provided to HIV/AIDS patients since
986. An observational, longitudinal, clinical database has
een maintained on patients receiving primary HIV care
n the clinic. Data are updated regularly using outpatient
nd inpatient clinical documentation, laboratory testing
esults, and pharmacy records. Trained abstractors record
ll this information onto standardized forms for process-
ng. Details of the methodology have been previously
escribed.10For this cross sectional study, we included retrospec-
ive data from all patients over 18 years of age who
ave had at least one follow-up appointment (clinical visit,
ab exams, antiretrovirals (ARV) reload, social assistance3;17(3):324–331 325
interview) between January 1st, 2008 and December 31st, 2008
(n=2307). This study was approved by IPEC/FIOCRUZ ethics
committee.
Study deﬁnitions
Age in 2008 was the variable of interest across all analyses.
Patients were stratiﬁed as 18–39 years (“younger patients”),
40–49 years (“older patients”); 50–59 years and ≥60 years
(“elderly patients”), according to CDC criteria.4 Other variables
used to describe our cohort included demographic, clinical
and treatment related characteristics.
For “years since HIV-infection”, we considered the period
between the ﬁrst HIV positive test available and 31 December
2008.
“Viral suppression” was deﬁned as viral load less than 400
HIV RNA copies/L at all available viral load assessments per-
formed during 2008. For “Last CD4 cells/L” the last CD4+ T
lymphocyte count available in 2008 was considered, while for
“Nadir CD4 cells/L” all historical CD4 results available until
31 December 2008 were considered.
For “Era of starting antiretroviral therapy (ART)”, we clas-
siﬁed patients who started using mono/dual (one or two ARV
only) or HAART. To classify “ART-naïve” and “current HAART
regimen” only year 2008 information was considered. We have
also accessed the number of patients on use of new ARV
(etravirine, enfurvitide, raltegravir and darunavir).
For “Comorbidities” (diabetes mellitus, dyslipidemia,
hypertension, depression and erectile dysfunction) we con-
sidered the cases under speciﬁc drug intervention during
the year 2008. Data were collected from medical prescrip-
tions and medical charts. For “cardiovascular diseases” other
than hypertension, reports of cardiac arrhythmia, heart
failure, coronary disease, ischemic heart disease, periph-
eral vascular insufﬁciency and stroke were considered. For
Hepatitis B (HBV), we considered all patients with a pos-
itive HBV surface antigen (HBsAg) exam. For Hepatitis C
(HCV), we considered all patients with an anti-HCV positive
test.
“Renal dysfunction” was deﬁned as a glomerular ﬁltration
rate (GFR) lower than 60mL/min calculated by the CKD-EPI
for all patients who had a creatinine result in 2008 (n=1971;
85.4%). Patients with hospitalization history within six-month
interval of the creatinine result were excluded to avoid bias
with acute renal disease (n=37; 1.6%).
For “AIDS deﬁning illness”, “AIDS-deﬁning cancer” and
“non-AIDS-deﬁning cancer” all diagnoses until 2008 were con-
sidered. We used the Centers for Disease Control (CDC, 1993)
for “AIDS deﬁning illness”.
Statistical analysistrend. For categorical variables, the Cochran–Armitage non-
parametric test for trend was used. For all tests, the threshold
for statistical signiﬁcance was set at 5%. Analyses were done
using R-software (version 2.14.2).
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Fig. 1 – Number of comorbidities of HIV/AIDS patients from
IPEC/FIOCRUZ cohort, Rio de Janeiro, Brazil, stratiﬁed by age326 braz j infect d
Results
Demographic data
Selected demographic values distributed according to the
decade of life are summarized in Table 1. A total of 2307
patients were included in this analysis. From these, 1023
(44.3%) were 18–39 years, 823 (35.7%) were 40–49 years, 352
(15.3%) were 50–59 years, and 109 (4.7%) were ≥60 years. Each
age stratum had more male (overall average of 63.6%) and
white (overall average of 57.2%) patients.
The proportion of MSM and of non-whites signiﬁcantly
ﬂuctuated over the age groups (p=0.021 and p<0.001, respec-
tively). MSM Transmission Group was less frequent among
elderly (49.3% for 50–59 years; 53.2% for ≥60 years).
There were no statistically signiﬁcant differences in years
of education and enrollment in anART clinical trial among the
age groups.
Treatment and clinical status
HIV treatment and clinical status distributed according to the
decades of life are depicted in Table 1. The median age at HIV
diagnosis and years since HIV infection signiﬁcant increased
(p<0.001) with age. Consequently, other variables related to
ART use (e.g. number of years on ART, use of mono/dual ther-
apy, use of PI-based regimen, use of new ARV) also increased
with age, while the proportion of ARV-naïve patients signiﬁ-
cantly decreased with age (p<0.001).
We found a higher proportion of viral suppression among
older and elderly patients (p<0.001). There was no signiﬁcant
difference in the latest CD4+ T lymphocyte count in the differ-
ent age strata. However, older and elderly patients had lower
CD4+ T lymphocyte nadir (p<0.020).
Comorbidities, smoking status and other characteristics
The number of comorbidities increased with age (Fig. 1). The
same pattern was observed for the majority of the comorbidi-
ties, including diabetes mellitus, dyslipidemia, hypertension,
cardiovascular diseases, erectile dysfunction, HCV, renal dys-
function and also for non-AIDS-related cancers (p<0.001)
(Table 2).
Depression was observed in 14.3%, 18.8%, 23.3% and 19.3%
of individuals aged 18–39 years, 40–49 years, 50–59 years
and ≥60 years, respectively (p<0.001). Use of anxiolytics was
observed in 15.0%, 20.8%, 23.9% and 14.7% for the groups
aged 18–39 years, 40–49 years, 50–59 years and ≥60 years,
respectively (p=0.005). For AIDS-deﬁning illnesses, there was
a higher proportion of these complications among older and
elderly patients (58.1% and 56.0%, respectively) as compared
to younger patients (44.6%; p<0.001). There was no signiﬁ-
cant difference in the proportion of patients with HBV and
AIDS-related cancers among the different age groups.
Overall, 27% (507 individuals) were current smokers. There
was no signiﬁcant difference on current smoking status by age
strata. However, only 9.8% of patients aged≥60 yearswere cur-
rent smokers, whereas values for patients aged 18–39 years,
40–49 years and 50–59 years were 27.8%, 27.4% and 28.5%,in 2008.
respectively. A higher proportion of elderly patients had quit
smoking (p<0.001), and a greater proportion of patients who
never smokedwere found in the younger (55.3%) and≥60 years
(48.8%) age strata (p<0.001).
Among women in different age strata we found no differ-
ences inhormoneuse (either for contraceptionor replacement
therapy). Menopause was observed in 1.0%, 22.7%, 79.2% and
100% of individuals aged 18–39 years, 40–49 years, 50–59 years
and≥60 years, respectively (p<0.001). Overall, 24.5%ofwomen
had undergone menopause.
Discussion
Our results show that there are important variations in several
aspects related to HIV infection across the life decades.
Demographic and clinical parameters varied with age in
our cohort. Individuals considered elderly (≥50 years) com-
prised 20% of our cohort, which is low when compared to
cohorts from resource rich countries. In the Swiss cohort, for
instance, 26% of individualswere 50–64 years old, and 5%were
≥65 years old.7 We found a men to women HIV infection ratio
of 1.7, which is similar to the ratio observed in the overall HIV
population in Brazil and Rio de Janeiro State,5 but lower than
cohorts from developed countries.9,11
Whites were more prevalent in all age groups. Never-
theless, the difference between whites and non-whites was
higher among older and elderly individuals. This is in accor-
dance with the trends of the Brazilian epidemic, if we assume
race as a proxy for social strata.5
Elderly men (≥50 years) reported less MSM exposure as HIV
risk category when compared to younger and older men. The
same results have been observed in other studies in Spain
and the USA.11,12 This may be related to the fact that elderly
individuals may not be comfortable with reporting MSM sex-
ual practices. It has been reported that men at this age are
more prone to having sex with multiple partners or to not
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Table 1 – Demographics, HIV treatment and clinical status of HIV/AIDS patients from IPEC/FIOCRUZ cohort, Rio de
Janeiro, Brazil, stratiﬁed by age in 2008.
Variable 18–39 40–49 50–59 ≥60 Total p-Value
(n=1023) (n=823) (n=352) (n=109) (n=2307)
Sex: Men, n (%) 631 (61.7) 542 (65.9) 228 (64.8) 67 (61.5) 1468 (63.6) 0.335
HIV transmission group: MSMa 331 (60.7) 301 (63.6) 101 (49.3) 33 (53.2) 766 (59.6) 0.021
Race: Non-white 473 (46.4) 334 (40.6) 134 (38.1) 44 (40.4) 985 (42.8) 0.004
Education: <4 years, nr. (%) 264 (25.8) 171 (20.8) 93 (26.6) 42 (38.5) 570 (24.7) 0.150
ART clinical trial enrolment, nr. (%) 447 (44.3) 347 (43.1) 148 (43.1) 35 (33.6) 977 (43.2) 0.129
Age at HIV diagnosis, years <0.001
Mean (SD) 27.3 (5.9) 35.9 (6.1) 44.2 (6.5) 55.1 (7.1) 34.3 (9.8)
Median (IQR) 27.4 (23.7–31.4) 36.0 (31.5–40.6) 44.0 (39.4–49.1) 54.3 (50.4–59.7) 33.1 (27.3–40.2)
Years since HIV-infection <0.001
Mean (SD) 5.2 (4.4) 9.1 (5.7) 10.1 (5.8) 10.9 (5.6) 7.6 (5.6)
Median (IQR) 3.5 (1.9–8.0) 8.8 (3.8–13.5) 10.2 (4.9–15.3) 11.5 (7.1–15.4) 6.9 (2.6–11.7)
Viral suppression, nr. (%) 472 (50.4) 458 (61.6) 194 (60.6) 59 (57.3) 1183 (56.2) <0.001
Last CD4 cells/L 0.490
Mean (SD) 477 (378) 491 (299) 590 (1372) 497 (309) 501 (620)
Median (IQR) 425 (298–605) 437 (299–624) 464 (287–657) 460 (279–690) 436 (294–622)
Nadir CD4 cells/L <0.020
Mean (SD) 243 (205) 197 (181) 191 (168) 188 (148) 217 (190)
Median (IQR) 220 (84–333) 163 (76–298) 160 (61–279) 169 (77–272) 184 (73–302)
ART-naïve, nr. (%) 251 (24.5) 93 (11.3) 32 (9.1) 5 (4.6) 381 (16.5) <0.001
Years on ART <0.001
Mean (SD) 4.6 (4.1) 7.4 (4.7) 8.5 (4.9) 8.8 (5.0) 6.5 (4.8)
Median (IQR) 3.0 (1.1–7.7) 7.8 (2.7–11.5) 9.5 (4.2–12.4) 9.8 (3.9–12.5) 6.4 (1.8–10.8)
Age at ART start, years, median (IQR) 28.5 (25.0–32.6) 37.2 (33.3–41.7) 45.4 (41.2–49.7) 56.7 (51.8–60.8) 35.4 (29.5–42.4) <0.001
Era of starting ART, nr. (%)
HAART 599 (78.2) 468 (65.1) 189 (59.2) 55 (53.4) 1311 (68.7) <0.001
Mono/Dual 167 (21.8) 251 (34.9) 130 (40.7) 48 (46.6) 596 (31.2)
Current HAART Regimen, nr. (%)
NNRTI 400 (51.8) 299 (41.0) 122 (38.1) 32 (30.8) 853 (44.3) 0.097
PI 330 (42.7) 374 (51.2) 180 (56.2) 62 (59.6) 946 (49.1)
Others 42 (5.4) 57 (7.8) 18 (5.6) 10 (9.6) 127 (6.6)
Use of new ARV, nr. (%)
Etravirine 10 (1.0) 28 (3.4) 8 (2.3) 5 (4.6) 51 (2.2) 0.003
Enfurvitide 9 (0.9) 28 (3.4) 14 (4.0) 3 (2.7) 54 (2.3) 0.001
Raltegravir 15 (1.5) 19 (2.3) 10 (2.8) 4 (3.7) 48 (2.1) 0.036
Darunavir 34 (3.3) 75 (9.1) 28 (7.9) 12 (11.0) 149 (6.5) <0.001
SD, standard deviation; IQR, interquartile range.
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a Only men were considered.
sing condoms,13 therefore behavioral interventions to pro-
ote condom use and other prevention strategies should be
valuated in this population.
Elderly individuals had a longer duration of HIV infection
hen compared with younger patients (10.1 years and 10.9
ears for patients aged 50–59 years and ≥60 years, respec-
ively). These values were lower than in the Swiss cohort
15.7 years for ages 50–64 years and 18.2 years for ages ≥65
ears).7 Elderly patients (≥50 years) in our cohortwere infected
ounger and are aging, whereas new HIV infections in older
ndividuals are less frequent, especially among those patients
ged ≥60 years. These ﬁndings suggest that our study popu-
ation actually is aging with HIV.
Last CD4+ T lymphocyte counts median was slightly higher
mong elderly patients, although this difference was not45); viral suppression (203); era of starting ART (19).
statistically signiﬁcant. This ﬁnding could be attributed to a
survival bias in older patients with higher CD4+ T lymphocyte
counts, or could merely be a reﬂection of HIV viral replica-
tion control after HAART introduction.14 As observed in other
cohorts, we found a higher proportion of older and elderly
patients who achieved virological responses with HAART
when compared with younger patients,7,11,15 and this could
be attributed to better adherence to ART.16 In a study con-
ducted in the US, elderly patients were more likely to achieve
superior virological responses within one year of HAART, but
adjustment for adherence attenuated this ﬁnding.17 Unfortu-
nately, there was no structured adherence evaluations for our
patient population.
Late presentation in HIV infection is common. Diagnosis
is usually done when the immunological system is already
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Table 2 – Distribution of smoking status, comorbidities, polipharmacy and other characteristics of HIV/AIDS patients from IPEC/FIOCRUZ cohort, Rio de Janeiro, Brazil,
stratiﬁed by age in 2008.
Variable 18–39 (n=1023) 40–49 (n=823) 50–59 (n=352) ≥ 60 (n=109) Total (n=2307) p-Value
Smoking status, nr. (%)
Current 226 (27.8) 187 (27.4) 86 (28.5) 8 (9.8) 507 (27.0) 0.067
Quit 137 (16.8) 209 (30.6) 125 (41.4) 33 (40.2) 504 (26.8) <0.001
Never 450 (55.3) 285 (41.8) 90 (29.8) 40 (48.8) 865 (46.0) <0.001
Comorbidities and polipharmacy, nr. (%)
Diabetes mellitus 2 (0.2) 14 (1.7) 15 (4.3) 5 (4.6) 36 (1.6) <0.001
Dislipidemia 49 (4.8) 139 (16.9) 81 (23.0) 32 (29.4) 301 (13.0) <0.001
Hypertension 57 (5.6) 109 (13.2) 76 (21.6) 33 (30.3) 275 (11.9) <0.001
Cardiovascular diseases 42 (4.1) 73 (8.8) 56 (15.9) 30 (27.5) 201 (8.7) <0.001
Estimated glomerular ﬁltration rate (CKD-EPI < 60mL/min) 13 (1.5) 26 (3.6) 20 (6.6) 20 (20.8) 79 (3.9) <0.001
Median CKD-EPI, mL/min (IQR) 120.1 (108.7–133.7) 107.8 (95.0–120.2) 100.1 (85.2–111.0) 92.0 (67.5–102.0) 111.3 (97.4–124.5) <0.001
Hepatitis B 29 (2.9) 25 (3.1) 9 (2.6) 2 (1.9) 65 (2.9) 0.580
Hepatitis C 26 (2.6) 53 (6.6) 42 (12.1) 13 (12.1) 134 (6.0) <0.001
Depression 146 (14.3) 155 (18.8) 82 (23.3) 21 (19.3) 404 (17.5) <0.001
Use of anxiolitics, nr. (%) 154 (15.0) 171 (20.8) 84 (23.9) 16 (14.7) 425 (18.4) 0.005
Non-AIDS-related cancers 6 (0.6) 15 (1.8) 8 (2.3) 6 (5.5) 35 (1.5) <0.001
Erectile dysfunctiona 11 (1.8) 32 (5.8) 19 (8.3) 7 (10.4) 69 (4.7) <0.001
Use of female hormones, nr. (%)b 71 (18.2) 32 (11.5) 18 (14.6) 4 (9.5) 125 (15.0) 0.053
Other characteristics, nr. (%)
Menopause, nr. (%)b 4 (1.0) 63 (22.7) 95 (79.2) 42 (100) 204 (24.5) <0.001
AIDS-related cancers, nr. (%) 21 (2.0) 38 (4.6) 12 (3.4) 3 (2.7) 74 (3.2) 0.115
AIDS-deﬁning illness, nr. (%) 456 (44.6) 478 (58.1) 197 (56.0) 61 (56.0) 1192 (51.7) <0.001
Death, nr. (%) 15 (1.5) 13 (1.6) 5 (1.4) 5 (4.6) 38 (1.6%) 0.158
SD, standard deviation; IQR, interquartile range.
Missing data: cardiovascular diseases (8); estimated glomerular ﬁltration rate (305), smoking status (427), Hepatitis B (67), Hepatitis C (70).
a Only men were considered.
b Only women were considered.
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ompromised and median values of CD4+ T lymphocyte
ounts are lower than 200 cels/mm3.18 Elderly individuals are
requently diagnosed even later than younger patients.19,20
nd this is reﬂected in the lower CD4+ T lymphocyte nadir
hat we observed among elderly patients in our cohort. Other
tudies in this population have also observed low CD4+ T lym-
hocyte nadir21 as well as worse clinical outcomes including a
horter time between HIV identiﬁcation, AIDS diagnosis, and
urvival time.15 This may be related to the lower level of sus-
icion of HIV diagnosis among older adults.19
Because older patients have longer durations of HIV infec-
ion, it was expected that this population would be on ART for
longer period of time. According to the Brazilian guidelines,
NRTI-based HAART should be the preferred ﬁrst-line regi-
en, and PI regimens as second-line and salvage regimens.22
his could explain the higher prevalence of younger indi-
iduals on NNRTI while among older and elderly patients
I-based regimens were more widely used. This was also
bserved for the use of new drugs (enfurvitide, raltegravir,
travirine and darunavir), although their overall use is still
ow among all age groups. This could be attributed to the fact
hat these new drugs can only be used as salvage regimens
ccording to Brazilian ART guidelines.22
Theprevalence of current smokers in our cohortwashigher
han for the Brazilian general population (27.0% vs. 15.5%).23
he prevalence of smoking is usually higher in HIV-infected
atients than in the HIV-negative population. Patients aged
60 years had the lowest prevalence of current smoking
9.76%), probably due to the fact that many of those older past
mokers have already quit smoking. The sameproﬁle has been
bserved in other cohorts from resource rich countries.7,14
Consistent with the literature, 74.3% of our patients ≥60
ears and 61.4% of patients aged 50–59 had at least one
omorbidity.24,25 In the Brazilian general population, 65% of
ndividuals aged 50–64 years and 79.1% aged≥65 years have at
east one chronic disease.26 Results from a recent study con-
ucted in Italy showed that the prevalence of two or more
omorbidities in HIV patients aged 40 years was similar to a
ontrol group of HIV-negative patients aged 55 years, which
ay be translated as premature aging by 15 years.27
The prevalence of diabetes mellitus in Brazilians aged ≥18
ears is 5.2%,2 and the current estimated prevalence in the
orld population is 4.1%.28 These rates are greater than the
verall diabetes prevalence (1.6%) in our cohort but similar to
he rate observed in the elderly group. The prevalence of dia-
etesmellitus amongHIV-infected patients onART in a cohort
rom the US (median age of 48 years) has been reported to
e more than 4-fold higher than among seronegative control
roups.29 It is important to highlight that our studywasmostly
omprised by a larger proportion of younger people. Moreover,
e have used a strict deﬁnition for diabetes in our study, as we
nly considered as having diabetes those patients who were
sing speciﬁc treatment.
As expected, an association between age and dyslipidemia
as observed in our study, with a prevalence of 23% for
hose patients aged 50–59 years, similar to the observed for
atients on lipid-lowering agents aged 50–65 years in the Swiss
ohort.7
Hypertension was detected in 11.9% of all patients in our
tudy, which is similar to the prevalence of hypertension3;17(3):324–331 329
controlled by antihypertensive agents in the Brazilian general
population (14.8%).30 Comparing the age groups, the preva-
lence was 30.3% for patients aged ≥60 years and 21.6% for
patients aged 50–59 years whereas it was 5.6% and 13.2%
among those patients aged 18–39 and 40–49, respectively.
Thesedata are comparable to aHIV/AIDS cohort from theUS.31
Patients with HIV/AIDS have a higher risk of cardiovascu-
lar diseases (CVD) in the long-term.8 In our cohort, there was
a higher prevalence of CVD among elderly patients (15.9% and
27.5%, for 50–59 and ≥60 years, respectively) compared with
younger patients, which is higher than the rates observed for
the Brazilian general population (8.5%and 15.9%, for 50–64 and
≥65 years, respectively)32 and higher than HIV/AIDS cohorts
fromSpain (13%)11 and Italy (16%).27 It is important tonote that
the prevalence of tobacco use in our cohort is high, increas-
ing the risk of CVD. Assessment of risk factors followed by
targeted interventions for risk reduction are critical steps for
CVD prevention in this patient population.
Glomerular ﬁltration rates (GFR) usually decrease with
age, and individuals over 60 years have 20–30% lower GFR
than those younger than 50 years.33 The prevalence of GFR
<60mL/min in our population was 3.9%, higher than the rate
observed in the UK CHIC cohort (2.0%).34 As expected, there
was a signiﬁcant difference in the proportion of reduced GFR
among patients≥60 years (20.8%) and 50–59 years (6.6%) when
compared to younger patients (1.5%; p<0.0001), consistent
with what was observed in other cohorts.9,11 Earlier ART initi-
ation, renal toxicity monitoring and appropriate comorbidity
management are key interventions to preserve a heathy renal
function among the HIV/AIDS patients who are getting older.
The prevalence of depression in our cohortwas higher than
the worldwide prevalence (17.5% vs. 4.10%) but lower than
that observed in other HIV cohort studies of other countries,
which varied from 20% to 79% depending on the population
studied, the duration of the study and the parameters used
to deﬁne depression.35,36 This may be related to our restric-
tive deﬁnition of depression including only those patients on
antidepressants. Patients with milder depression may have
been excluded. We observed a high proportion of depression
among the older and elderly. A similar proﬁle was observed in
the Swiss cohort, although in other cohorts the prevalence of
depression was higher only among patients aged ≥60 years.37
The same pattern was observed for the use of anxiolytics
(BZD); 18% of our population regularly used one BZD, which
is similar to the observed in a cross-sectional survey of 2932
HIV-infected patients in France (16%)38 and much higher than
the observed rate in the overall Brazilian population (5.6%).39
This ﬁnding highlights the additional burden related to HIV
infection and its impact on the quality of life of people living
with HIV/AIDS.40
In various studies, when compared to the general popu-
lation, elderly patients with HIV/AIDS had a relative risk of
1.3 for all non-AIDS-related cancers, especially those related
to chronic infections (HPV-anal cancer, Epstein Barr-Hodgkin’s
disease, and Hepatitis B and C-liver cancer).41,42 Cancer preva-
lence in our study was higher among patients aged ≥60 years
compared with patients aged 50–59 years (5.5% vs. 2.3%) but
lower than that observed in the literature for the elderly
(13%).11 The most frequently diagnosed cancers in our cohort
were skin (37.5%), rectum/anus (18.7%), breast and uterus
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(9.4% each), lung and stomach (6.2% each), larynx, intestine,
prostate and kidney (3.1% each). In the USA HIV/AIDS popu-
lation, approximately 50% of the estimated non-AIDS-related
cancers (n=9645) were cases of lung cancer, anal cancer, liver
cancer, and Hodgkin lymphoma, which are known to occur
more frequently among peoplewithHIV.43 In the Swiss cohort,
the most frequent cancers were lung (10.3%), prostate (7.1%),
and skin (5.6%).7 The fact that Brazil is a tropical country and
our Institution is located in a beach town could explain the
high proportion of skin cancers, which are probably related
to non-protected solar exposure. Anal cancer is one of the
most common cancers affecting individuals infected with
HIV. In a study involving 13 cohorts from North America,
anal cancer rates were substantially higher for HIV-infected
MSM, other men, and women compared with HIV-uninfected
individuals.44
Prevalence of erectile dysfunction (ED) among male
patients aged ≥60 and 50–59 years (10.5% and 8.3%, respec-
tively) could have been underestimated due to the absence
of free ED drugs available in our hospital, patients failing to
report ED drug use, or even the lack of information on ED
reported by health professionals. However, these results are in
agreement with a previous study from São Paulo (Brazil) with
general population, where 12.3% of patients aged ≥60 years
and 6.7% of patients aged 50–59 years reported ED.45 In a MSM
cohort in California, it was veriﬁed that HIV-infected MSM
with advanced disease had signiﬁcantly increased odds for
ED when compared to HIV-negative men while HIV-infected
MSM with no evidence of AIDS appeared to have a slightly (but
statistically nonsigniﬁcant) increase in odds for ED.46 These
prevalences are higher than those found in our study, proba-
bly because they were based on self-reported questionnaires,
not restricted to assess the use of ED medications.
We have observed a high prevalence of menopause among
women between the ages of 40 and 49 years (22.7%), in accor-
dance with data reported by the Women’s Interagency HIV
Study that found that median age for menopause was 47.7
years-old.47 In the general population, the median age at
menopause is 51 years.48 HIV-infected women tend to reach
menopause younger, on average at the age of 46 years.49 De
Pommerol and colleagues observed that the average age was
49 years and identiﬁed an association with earlier menopause
in women with more advanced immunosuppression, deﬁned
as lymphocyte T CD4+ counts <200 cells/mm3,50
It is important to highlight that the lifestyle of people liv-
ing with HIV can be different within the HIV context itself
and also when compared to the general population. Moreover,
the impact of the traditional risk factors may also differ both
among distinct groups of people living with HIV, as in the gen-
eral population. These differences may affect the frequency
and the outcomes of the different comorbidities. Finally, these
differences can be crucial to deﬁne better strategies for the
prevention, early identiﬁcation and treatment of the comor-
bidities.
In summary, we have observed a higher prevalence of
non-AIDS comorbidities, particularly cardiovascular disease,
dyslipidemia, renal disease, depression and non-AIDS-
deﬁning malignancies among elderly patients. Our data
also suggest that menopause may occur earlier among HIV
infected women, as observed in other cohorts. Of note, due
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to the cross-sectional design of our study, causal associations
cannot be inferred. Moreover, the retrospective nature of the
work, and the lack of more detailed information in medical
charts/database on some speciﬁc aspects of medication use
are potential causes of underestimation of some events such
as ED and depression.
With the survival increase associated to successful ART,
coupled with the higher rates of new HIV infections among
this age group, the burden associated with the diagnosis and
treatment of non-AIDS related HIV comorbidities will grow
substantially. These results point out the importance of a
comprehensive approach in the clinical management of the
HIV/AIDSpopulation, including risk factors reduction andpre-
ventive screening procedures. Longitudinal studies on the
impact of aging on the HIV/AIDS population are warranted,
especially in resource-limited countries.
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